Showing results (1351-1360 of 1,689) with videos related to

Sort By:
Pageof 169
European Journal of Heart Failure|August 26, 2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HFSenthil Selvaraj, Brian L Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure|May 21, 2023
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA-HFSafia Chatur, Toru Kondo, Brian L Claggett, et al.
JACC. Heart Failure|August 20, 2025
Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection FractionSara R O Siqueira, Maria A Pabon, Muthiah Vaduganathan, et al.
European Heart Journal|August 26, 2022
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillationToru Kondo, Azmil H Abdul-Rahim, Atefeh Talebi, et al.
BMJ Open|March 8, 2024
Multicomponent (bio)markers for obesity risk prediction: a scoping review protocolFarhad Vahid, Coralie Dessenne, Josep A Tur, et al.
JACC. Asia|November 7, 2022
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFKieran F Docherty, Inder S Anand, Chern-En Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2019
Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective StudyStephen J Bagley, S Ali Nabavizadeh, Jazmine J Mays, et al.
The Lancet. Diabetes & Endocrinology|November 13, 2022
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trialSilvio E Inzucchi, Brian L Claggett, Muthiah Vaduganathan, et al.
JACC. Heart Failure|May 25, 2023
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Jorge Thierer, Brian L Claggett, et al.
Circulation|November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trialMarc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
Pageof 169